CERO THERAPEUTICS HOLDINGS INC
For the period ended Dec 31, 2023. Filed Apr 2, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 2, 2024
CERO$0.00-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Deficit
FOR THE YEAR ENDED DECEMBER 31, 2023 AND 2022
| Common stock · Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Class A · Class B · paid-in · Accumulated · Stockholders’ | |||||||
| Shares | Amount | Shares | Amount | capital | deficit | Deficit | |
| Balance, December 31, 2021 | 885,000 | $88 | 4,596,250 | $459 | $— | $(7,670,412) | $(7,669,865) |
| Accretion for Class A Common Stock Subject to Redemption | — | — | — | — | — | (2,662,553) | (2,662,553) |
| Net loss | — | — | — | — | — | (667,736) | (667,736) |
| Balance, December 31, 2022 | 885,000 | 88 | 4,596,250 | 459 | — | (11,000,701) | (11,000,154) |
| Accretion for Class A Common Stock Subject to Redemption | — | — | — | — | — | (606,346) | (606,346) |
| Excise tax liability accrued for Class A common stock redemptions | — | — | — | — | — | (56,389) | (56,389) |
| Conversion of Class B common stock to Class A common stock | 4,596,250 | 459 | (4,596,250) | (459) | — | — | — |
| Net loss | — | — | — | — | — | (2,536,233) | (2,536,233) |
| Balance, December 31, 2023 | 5,481,250 | $547 | — | $— | $— | $(14,199,669) | $(14,199,122) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.